BR0013349A - Processo para preparar uma formulação para liberação sustentada - Google Patents

Processo para preparar uma formulação para liberação sustentada

Info

Publication number
BR0013349A
BR0013349A BR0013349-3A BR0013349A BR0013349A BR 0013349 A BR0013349 A BR 0013349A BR 0013349 A BR0013349 A BR 0013349A BR 0013349 A BR0013349 A BR 0013349A
Authority
BR
Brazil
Prior art keywords
preparing
sustained release
release formulation
compound
lgt
Prior art date
Application number
BR0013349-3A
Other languages
English (en)
Inventor
Thomas Ciaran Loughman
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Publication of BR0013349A publication Critical patent/BR0013349A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Patente de Invenção: "PROCESSO PARA PREPARAR UMA FORMULAçãO PARA LIBERAçãO SUSTENTADA". Esta invenção refere-se a um processo para preparar um complexo de liberação sustentada, Composto (I), o qual compreende o Composto (A), tendo fórmula (A), e um copolímero compreendendo ácido poli-(I)-láctico-glicólico-tartárico (P(I)LGT), em que o grupo amino do Composto (A) é ligado ionicamente a um grupo carboxila do P(I)LGT.
BR0013349-3A 1999-08-18 2000-08-14 Processo para preparar uma formulação para liberação sustentada BR0013349A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation
PCT/IE2000/000099 WO2001012232A2 (en) 1999-08-18 2000-08-14 Process to make a sustained release formulation

Publications (1)

Publication Number Publication Date
BR0013349A true BR0013349A (pt) 2002-04-23

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013349-3A BR0013349A (pt) 1999-08-18 2000-08-14 Processo para preparar uma formulação para liberação sustentada

Country Status (26)

Country Link
US (1) US6893645B1 (pt)
EP (1) EP1212095B1 (pt)
JP (1) JP3730917B2 (pt)
CN (2) CN1823736A (pt)
AR (1) AR022647A1 (pt)
AT (1) ATE243044T1 (pt)
AU (1) AU755229B2 (pt)
BR (1) BR0013349A (pt)
CA (1) CA2380902C (pt)
CZ (1) CZ294433B6 (pt)
DE (1) DE60003438T2 (pt)
DK (1) DK1212095T3 (pt)
ES (1) ES2195925T3 (pt)
HK (1) HK1044285A1 (pt)
HU (1) HUP0202895A3 (pt)
IE (1) IES990700A2 (pt)
IL (1) IL148044A0 (pt)
MX (1) MXPA02001415A (pt)
NO (1) NO20020762L (pt)
NZ (1) NZ517251A (pt)
PL (1) PL199862B1 (pt)
PT (1) PT1212095E (pt)
RU (1) RU2211694C1 (pt)
TW (1) TWI230069B (pt)
WO (1) WO2001012232A2 (pt)
ZA (1) ZA200202027B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203060A3 (en) * 1999-08-18 2003-11-28 Sod Conseils Rech Applic Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
JP5183068B2 (ja) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ 大気噴出凍結乾燥法による粉末形成
JP2008518026A (ja) 2004-10-27 2008-05-29 ユニバーシティ・オブ・デンバー 副腎皮質刺激ホルモンアナログおよびこれに関連する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2150574A1 (en) * 1993-01-06 1994-07-21 Shalaby W. Shalaby Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ATE284413T1 (de) 1993-08-09 2004-12-15 Sod Conseils Rech Applic Therapeutische peptid derivate
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
PL342135A1 (en) 1998-01-29 2001-05-21 Kinerton Ltd Method of obtaining absorbable microparticle
EP1043079A4 (en) 1998-08-28 2005-03-16 Mitutoyo Corp AUTOMATIC DEVICE FOR WASHING WORKPIECES BEFORE MEASURING AND AUTOMATIC PRODUCTION SYSTEM EQUIPPED WITH THIS AUTOMATIC WASHING DEVICE
HUP0203060A3 (en) * 1999-08-18 2003-11-28 Sod Conseils Rech Applic Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
CZ2002266A3 (cs) 2002-05-15
MXPA02001415A (es) 2002-08-12
ZA200202027B (en) 2002-12-24
CN1377283A (zh) 2002-10-30
CA2380902A1 (en) 2001-02-22
WO2001012232A2 (en) 2001-02-22
JP2003507346A (ja) 2003-02-25
CN1823736A (zh) 2006-08-30
IL148044A0 (en) 2002-09-12
ES2195925T3 (es) 2003-12-16
DE60003438T2 (de) 2004-05-06
HUP0202895A3 (en) 2003-11-28
CZ294433B6 (cs) 2005-01-12
NO20020762L (no) 2002-04-16
DE60003438D1 (de) 2003-07-24
TWI230069B (en) 2005-04-01
IES990700A2 (en) 2001-08-22
PL354263A1 (en) 2003-12-29
EP1212095A2 (en) 2002-06-12
PL199862B1 (pl) 2008-11-28
ATE243044T1 (de) 2003-07-15
AR022647A1 (es) 2002-09-04
CA2380902C (en) 2008-08-05
WO2001012232A3 (en) 2002-04-04
RU2211694C1 (ru) 2003-09-10
RU2002106809A (ru) 2004-01-20
JP3730917B2 (ja) 2006-01-05
CN1246040C (zh) 2006-03-22
AU755229B2 (en) 2002-12-05
US6893645B1 (en) 2005-05-17
NO20020762D0 (no) 2002-02-15
NZ517251A (en) 2003-08-29
DK1212095T3 (da) 2003-10-06
WO2001012232A8 (en) 2002-06-06
AU6464700A (en) 2001-03-13
EP1212095B1 (en) 2003-06-18
PT1212095E (pt) 2003-10-31
HK1044285A1 (en) 2002-10-18
HUP0202895A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
FR17C0003I2 (fr) Steroides comme agonistes de fxr
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
NZ510012A (en) Compositions comprising sympathomimetic amine salts unsuitable for illegal use
BR0107837A (pt) Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
BR0214438A (pt) Composição farmacêutica para absorção nasal
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
BR9813989A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição
HRP20020428B1 (en) Bicyclic amino acids as pharmaceutical agents
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
WO2001012233A3 (en) Sustained release formulation of a peptide
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
YU52000A (sh) Jedinjenja meta-azaciklične amino benzojeve kiseline i njihovi derivati, koji su antagonisti integrina
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
BR0210531A (pt) Derivados de ácido sulfÈnico
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
ES2185911T3 (es) Composiciones farmaceuticas que contienen polimeros de ortoester tamponados.
HUP0202881A2 (hu) Antisztatikum
PT1336407E (pt) Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
BR0013349A (pt) Processo para preparar uma formulação para liberação sustentada
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
BR0009265A (pt) Derivados com base em esfingóide e usos destes
ATE312626T1 (de) Mucoadhäsive, wärmeaktivierbare zubereitung als träger für medikamente
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/69 (2017.01), A61K 47/59 (2017.01), A61K 4